GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Recent scientific research has highlighted the crucial role of GPCRs as membrane receptors within the tumour microenvironment where their role significantly impacts intercellular signalling. This discovery has produced a new pool of potential therapeutic targets, which are now becoming accessible thanks to advanced structure-based drug design techniques.
Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Each member of the GIO team brings a unique set of skills and experiences, all united by a shared passion for drug discovery and a history of building and creating successful companies.
At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. We welcome like-minded organisation and professionals to get in touch.
GIO Therapeutics is a proud venture of Cumulus Oncology.
Company Details
- Employees
- 4
- Founded
- 2024
- Address
- Lichtstrasse 35, Wsj 210,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://giotherapeutics.com/
- Keywords
- in this area..
- HQ
- Basel, BS
Gio Therapeutics Questions
Gio Therapeutics's website is https://giotherapeutics.com/
Gio Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/gio-therapeutics
Gio Therapeutics has
4 employees.
View email and phone details for 4
employees at Gio Therapeutics.
Gio Therapeutics's industry is
Biotechnology Research
Gio Therapeutics's top competitors are
Leadxpro Ag,
Fatiabgen Inc.,
Abbelight,
Cumulus Oncology,
Forx Therapeutics,
Nodus Oncology,
Aurealis Therapeutics,
Interax Biotech,
Ervimmune,
Blue Bees Therapeutics.
Gio Therapeutics's categories are Biotechnology Research
Gio Therapeutics's founding year is 2024
